Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This research is being done because melanoma in the brain is very difficult to treat because
it does not respond to radiation or to chemotherapy, such as temozolomide. One of the reasons
for this is that the melanoma can make chemicals that signal the brain to provide new blood
vessels for the tumor. The main signal is called VEGF. Bevacizumab is an antibody that blocks
VEGF. The investigators want to see if the combination of bevacizumab and temozolomide will
stop the melanoma from growing.